Literature DB >> 7884851

Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

A M Borman1, C Quillent, P Charneau, C Dauguet, F Clavel.   

Abstract

Disruption of the vif gene of human immunodeficiency virus (HIV) type 1 affects virus infectivity to various degrees, depending on the T-cell line used. We have concentrated our studies on true phenotypic Vif- mutant particles produced from CEMx174 or H9 cells. In a single round of infection, Vif- virus is approximately 25 (from CEMx174 cells) to 100 (from H9 cells) times less infectious than wild-type virus produced from these cells or than the Vif- mutant produced from HeLa cells. Vif- virions recovered from restrictive cells, but not from permissive cells, are abnormal both in terms of morphology and viral protein content. Notably, they contain much reduced quantities of envelope proteins and altered quantities of Gag and Pol proteins. Although wild-type and Vif- virions from restrictive cells contain similar quantities of viral RNA, no viral DNA synthesis was detectable after acute infection of target cells with phenotypically Vif- virions. To examine the possible role of Vif in viral entry, attempts were made to rescue the Vif- defect in H9 cells by pseudotyping Vif+ and Vif- HIV particles with amphotropic murine leukemia virus envelope. Vif- particles produced in the presence of HIV envelope could not be propagated when pseudotyped. In contrast, when only the murine leukemia virus envelope was present, significant propagation of Vif- HIV particles could be detected. These results demonstrate that Vif is required for proper assembly of the viral particle and for efficient HIV Env-mediated infection of target cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884851      PMCID: PMC188871     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus.

Authors:  P Sonigo; M Alizon; K Staskus; D Klatzmann; S Cole; O Danos; E Retzel; P Tiollais; A Haase; S Wain-Hobson
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

2.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

5.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

6.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus.

Authors:  B Sugden; K Marsh; J Yates
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

8.  Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.

Authors:  N C Kan; G Franchini; F Wong-Staal; G C DuBois; W G Robey; J A Lautenberger; T S Papas
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

9.  Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.

Authors:  H R Gelderblom; E H Hausmann; M Ozel; G Pauli; M A Koch
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

10.  Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses.

Authors:  L Chakrabarti; M Guyader; M Alizon; M D Daniel; R C Desrosiers; P Tiollais; P Sonigo
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

View more
  71 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Functional analysis of vif genes derived from various primate immunodeficiency viruses.

Authors:  Y Yamamoto; Y Saito; S Iida; J Asano; S Sone; A Adachi
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

6.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.

Authors:  V Maréchal; M C Prevost; C Petit; E Perret; J M Heard; O Schwartz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.

Authors:  Roger G Ptak; Brian G Gentry; Tracy L Hartman; Karen M Watson; M Clayton Osterling; Robert W Buckheit; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  HIV-1 Vif and APOBEC3G: multiple roads to one goal.

Authors:  Joao Goncalves; Mariana Santa-Marta
Journal:  Retrovirology       Date:  2004-09-21       Impact factor: 4.602

10.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.